Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery

NCT02827838 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT02827838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02827838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2017
Completion date
April 22, 2022
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus infection, stage i oral cavity squamous cell carcinoma, stage i oropharyngeal squamous cell carcinoma, stage ii oral cavity squamous cell carcinoma, stage ii oropharyngeal squamous cell carcinoma, stage iii oral cavity squamous cell carcinoma, stage iii oropharyngeal squamous cell carcinoma, stage iva oral cavity squamous cell carcinoma, stage iva oropharyngeal squamous cell carcinoma, stage ivb oral cavity squamous cell carcinoma, stage ivb oropharyngeal squamous cell carcinoma, stage ivc oropharyngeal squamous cell carcinoma